FIELD: pharmacology.
SUBSTANCE: invention relates to a compound of the formula
(1); where R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are different from hydrogen. The invention relates to a pharmaceutical composition for prevention or treatment of a disease mediated by Aurora A, Aurora B kinase or FLT3 kinase, comprising a therapeutic amount of a formula (1) compound, and a pharmaceutically acceptable excipient. The compounds are intended for use in treatment of a proliferative disease, a hematopoietic tumour selected from acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).
EFFECT: compounds for treatment of diseases mediated by Aurora A kinase, Aurora B or FLT3 kinase.
16 cl, 6 tbl, 18 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICALLY ACTIVE COMPOUNDS | 2013 |
|
RU2654942C2 |
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2387653C2 |
SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2568258C2 |
PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE PREVENTION OR TREATMENT OF CANCER | 2019 |
|
RU2807277C2 |
SUBSTITUTED INDOL-5-OL DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF | 2013 |
|
RU2674249C2 |
SUBSTITUTED N2-(4-AMINO-2-METHOXYPHENYL)-N4-[2-(DIMETHYLPHOSPHORYL)-PHENYL]-5-CHLORO-PYRIMIDINE-2,4-DIAMINES AS MODULATORS OF ALK AND EGFR, APPLICABLE FOR TREATING CANCER | 2015 |
|
RU2607371C1 |
BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | 2019 |
|
RU2806274C2 |
PROTEIN TYROSINE KINASE ACTIVITY INHIBITORS | 2009 |
|
RU2533827C2 |
CHEMICAL COMPOUNDS-759 | 2008 |
|
RU2481348C2 |
MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | 2011 |
|
RU2576036C2 |
Authors
Dates
2018-02-06—Published
2013-02-04—Filed